Opthea Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Fred Guerard

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	2.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Fred Guerard (51 yo)

less than a year

Permanencia

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Megan Baldwin	Founder	no data	US$1.57m	0.029% $ 94.7k
Judith Robertson	Chief Commercial Officer	2.4yrs	US$856.83k	sin datos
Karen Adams	VP of Finance & Company Secretary	3yrs	US$507.60k	sin datos
Frederic Guerard	Chief Executive Officer	less than a year	sin datos	sin datos
Peter Lang	Chief Financial Officer	less than a year	sin datos	sin datos
Sarika Gulhar	Executive Director of Human Resources	1.4yrs	sin datos	sin datos
Michael Gerometta	Head of Chemistry	15.5yrs	US$197.04k	sin datos
Bruno Gagnon	Senior Vice President of Global Clinical Operations	1.8yrs	sin datos	sin datos
Kenneth Sall	Chief Medical Officer	less than a year	sin datos	sin datos
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	sin datos	sin datos
Julie Clark	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos
Arshad Khanani	Chief Medical Advisor	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OPT no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Megan Baldwin	Founder	no data	US$1.57m	0.029% $ 94.7k
Jeremy Levin	Chairperson	3.7yrs	US$425.47k	0.0047% $ 15.3k
Jason Slakter	Member of Clinical Advisory Board	no data	sin datos	sin datos
Quinton Oswald	Independence Non-Executive Director	2.2yrs	US$202.36k	sin datos
Julia Haller	Independent Non-Executive Director	3yrs	US$327.41k	sin datos
Lawrence Gozlan	Independent Non-Executive Director	3.9yrs	US$724.31k	0.28% $ 910.5k
Sujal Shah	Non-Executive Director	less than a year	sin datos	sin datos
Anshul Thakral	Non-Executive Director	less than a year	US$3.16k	sin datos
Charles Wykoff	Member of Clinical Advisory Board	no data	sin datos	sin datos
Susan Orr	Independent Non-Executive Director	2.2yrs	US$206.20k	sin datos
Tim Jackson	Member of Clinical Advisory Board	no data	sin datos	sin datos

2.2yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de OPT no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Opthea Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Recent updates

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

New major risk - Financial position

New minor risk - Profitability

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.14 loss in FY 2021)

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.78

New 90-day low: AU$1.81

New 90-day low: AU$2.11

New 90-day low: AU$2.30

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

New 90-day high: AU$3.03

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

New 90-day high: AU$2.94

Opthea Limited(ASX:OPT) dropped from S&P/ASX Emerging Companies Index

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad